retinal vein occlusion

(redirected from Central Retinal Vein Occlusion)
Also found in: Medical, Acronyms, Wikipedia.

retinal vein occlusion

Blockage of the central vein or artery of the retina that sometimes results in blindness.
References in periodicals archive ?
Greenberg, "Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion," Cochrane Database of Systematic Reviews, vol.
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve month study results.
Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80(3):200-2.
Retinal vein occlusion (RVO) includes branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).
Some common causes of this serious secondary glaucoma are occlusive retinal vascular diseases such as central retinal vein occlusion (CRVO), proliferative diabetic retinopathy (PDR), central retinal artery occlusion (CRAO), inflammatory disease and intraocular tumours1.
The company added EYLEA was approved in the US for the treatment of Macular Edema following Central Retinal Vein Occlusion (CRVO) in September 2012.
None of the patients in our series developed retinal neovascularisation or iris neovascularisation, which could be due to small sample size of the study and less incidence of neovascularisation in BRVO as compared to CRVO (Central retinal vein occlusion).
VEGF levels did not differ among patients with neovascular glaucoma (NVG) secondary to proliferative diabetic retinopathy (PDR), central retinal vein occlusion (CRVO), and primary open-angle glaucoma (POAG).
Intravitreal triamcinolone for the management of macular oedema due to non-ischemic central retinal vein occlusion. Arch Ophthalmol 2004;122(8):1137-40.
Aflibercept solution for injection into the eye has already been approved under the brand name EYLEAA for the treatment of patients with neovascular age-related macular degeneration (wet AMD) and the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).
Biopharmaceutical company Regeneron Pharmaceuticals Inc (NasdaqGS:REGN) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for EYLEA for the treatment of Macular Edema following Central Retinal Vein Occlusion (CRVO.
Macular oedema (MO) secondary to RVO is the second-most common retinal vascular disease after diabetic retinopathy and is subdivided into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) based on the location of the occlusion [3].
Full browser ?